| Size | Price | Stock | Qty |
|---|---|---|---|
| 25mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| 250mg |
|
||
| 500mg |
|
||
| 1g |
|
||
| Other Sizes |
|
Purity: ≥98%
Rocuronium Bromide (ORG-9426; Zemuron; Esmeron; Esmeron; Esmerone) is a potent and competitive Nicotinic acetyl-choline receptors (AchR) antagonist, which is a non-depolarizing neuromuscular blocking agent used in anaesthesia required for surgery or mechanical ventilation. Rocuronium bromide is an aminosteroid type neuromuscular blocking agent acts by reducing or inhibiting the depolarising effect of acetylcholine on the terminal disc of the muscle cell.
| ln Vitro |
In a concentration-dependent manner, rocuronium decreased the indirectly elicited twitch tensions in all pretreated diaphragms (P <.01, n = 6) and normal (50% inhibitory concentration [IC(50)], 9.84 [9.64-10.04] μM, mean [95% confidence interval]) [1]. Rocuronium's ED95 for children and adults is nearly the same. Its half-life is shorter in children than in adults, and it functions similarly to vecuronium. It is easy to reverse rocuronium with standard dosages of cholinesterase-inhibiting medications [2]. The times for setting the maximum block, recovering the twitch height from 25% to 75%, and recovering the twitch height from 25% to 75% were 1.7 (32), 53 (19), and 20 (37) minutes, respectively [3].
|
||
|---|---|---|---|
| ln Vivo |
Merely 8.7±5.7% (SD) and 6.0±2.8%, respectively, of the administered dosages of ORG 9426 and ORG 9616 were eliminated through the urine. On the other hand, cats without renal pedicle ligation excreted 35.7±12.2% and 46.8±9.7% of ORG 9616 into the bile, and 54.4±9.2% and 52.4±9.2% of an administered dosage of ORG 9426, respectively [4].
|
||
| Animal Protocol |
|
||
| References |
[1]. Narimatsu E, Niiya T, Takahashi K, Pralidoxime inhibits paraoxon-induced depression of rocuronium-neuromuscular block in a time-dependentfashion. Am J Emerg Med. 2012 Jul;30(6):901-7.
[2]. Wicks TC. The pharmacology of rocuronium bromide (ORG 9426). AANA J. 1994 Feb;62(1):33-8. [3]. Wierda JM, Kleef UW, Lambalk LM, The pharmacodynamics and pharmacokinetics of Org 9426, a new non-depolarizing neuromuscular blocking agent, in patients anaesthetized with nitrous oxide, halothane and fentanyl. Can J Anaesth. 1991 May;38(4 Pt 1):430-5. [4]. Khuenl-Brady K, Castagnoli KP, Canfell PC, The neuromuscular blocking effects and pharmacokinetics of ORG 9426 and ORG 9616 in the cat. Anesthesiology. 1990 Apr;72(4):669-74. |
| Molecular Formula |
C32H53N2O4.BR
|
|
|---|---|---|
| Molecular Weight |
609.68
|
|
| CAS # |
119302-91-9
|
|
| Related CAS # |
Rocuronium;143558-00-3
|
|
| SMILES |
[Br-].O(C(C([H])([H])[H])=O)[C@@]1([H])[C@]([H])(C([H])([H])[C@@]2([H])[C@]3([H])C([H])([H])C([H])([H])[C@@]4([H])C([H])([H])[C@@]([H])([C@]([H])(C([H])([H])[C@]4(C([H])([H])[H])[C@@]3([H])C([H])([H])C([H])([H])[C@@]21C([H])([H])[H])N1C([H])([H])C([H])([H])OC([H])([H])C1([H])[H])O[H])[N+]1(C([H])([H])C([H])=C([H])[H])C([H])([H])C([H])([H])C([H])([H])C1([H])[H]
|
|
| InChi Key |
OYTJKRAYGYRUJK-UHFFFAOYSA-M
|
|
| InChi Code |
InChI=1S/C32H53N2O4.BrH/c1-5-14-34(15-6-7-16-34)28-20-26-24-9-8-23-19-29(36)27(33-12-17-37-18-13-33)21-32(23,4)25(24)10-11-31(26,3)30(28)38-22(2)35;/h5,23-30,36H,1,6-21H2,2-4H3;1H/q+1;/p-1
|
|
| Chemical Name |
[(2S,3S,5S,8R,9S,10S,13S,14S,16S,17R)-3-hydroxy-10,13-dimethyl-2-morpholin-4-yl-16-(1-prop-2-enylpyrrolidin-1-ium-1-yl)-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-17-yl] acetate;bromide
|
|
| Synonyms |
|
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
|
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
|
|---|
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.6402 mL | 8.2010 mL | 16.4020 mL | |
| 5 mM | 0.3280 mL | 1.6402 mL | 3.2804 mL | |
| 10 mM | 0.1640 mL | 0.8201 mL | 1.6402 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
|
|---|
|
|
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
COA
